Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

Clene Inc. (Nasdaq: CLNN) is set to participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025, in New York City. The company, along with its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical firm that focuses on enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Clene's management will be available for one-on-one investor meetings, providing an opportunity for potential investors to engage directly with the leadership team.

Founded in Salt Lake City, Utah, Clene specializes in the development of innovative therapies aimed at improving the survival and functionality of central nervous system cells. One of its key investigational therapies, CNM-Au8®, is a pioneering treatment designed to target mitochondrial function and the NAD pathway, while simultaneously reducing oxidative stress. This therapy represents a novel approach in the treatment of neurodegenerative conditions, showcasing Clene's commitment to addressing the challenges presented by these debilitating diseases.

The Benchmark conference format allows investors to have personalized interactions with company executives, fostering a deeper understanding of Clene's strategic initiatives, research developments, and investment potential. As it continues to advance its pipeline and strengthen investor relations, Clene is poised to make significant contributions to the field of neurology.

For more information about Clene and its innovative research, interested parties can visit the company’s website at www.clene.com or connect through social media platforms such as X (formerly Twitter) and LinkedIn. Investors can reach out to Kevin Gardner from LifeSci Advisors for inquiries related to the conference.

Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company, is gearing up to participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025, in New York City. This event provides Clene an invaluable platform to showcase its advancements in treating neurodegenerative diseases, prominently featuring its lead product, CNM-Au8®, which targets mitochondrial health and oxidative stress—a significant concern in conditions like Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).

From an investment perspective, this conference is strategically important for Clene as it looks to attract attention from potential investors and enhance market confidence in its initiatives. Given the growing awareness and urgency surrounding neurodegenerative diseases, Clene stands to benefit from increased investor interest. The company's innovative approach not only positions it as a leader in a promising therapeutic area but also aligns with current trends toward precision medicine and targeted therapies.

Investors should closely monitor the outcomes of these one-on-one meetings as they could provide insights into upcoming clinical trial results and strategic partnerships, critical indicators of Clene’s potential scalability and profitability. The company's commitment to improving mitochondrial health could set it apart in a competitive biopharmaceutical landscape, where effective treatment options for ALS and MS are still limited.

Moreover, stakeholders should factor in Clene's operational base in Salt Lake City, coupled with R&D facilities in Maryland, which may suggest operational efficiencies and innovation-driven growth. As always, investors should weigh Clene's potential against market dynamics, regulatory risks, and the broader biopharmaceutical environment. Thus, those interested in biopharmaceutical investments should consider Clene as a viable option, particularly in light of its innovative pipeline and an upcoming opportunity to engage directly with management at the Benchmark Conference.